Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.
The relationship between acetylator phenotype and the inhibitory effect of cimetidine on the hepatic metabolism of antipyrine has been studied in 20 subjects. Cimetidine, 1,0 g/day resulted in a significant decrease in the metabolic clearance rate of antipyrine, but only in slow acetylators, as fast acetylators were less affected. No sex difference was observed. No major change occurred in the urinary excretion of D-glucaric acid, which means that cimetidine had not-affected that Phase II reaction. It did significantly decrease the urinary partial clearance rate of norantipyrine, leaving that of antipyrine and 4-OH-antipyrine unchanged, which suggests that cimetidine had preferentially inhibited the P450 isozyme that catalyses norantipyrine formation.
D000107:Acetylation; D000328:Adult; D000983:Antipyrine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002927:Cimetidine / Q000494:pharmacology*; D000077553:Edaravone; D005260:Female; D005937:Glucaric Acid / Q000652:urine; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D010597:Pharmacogenetics; D010641:Phenotype
D002927:Cimetidine; D005937:Glucaric Acid; D000077553:Edaravone; D000983:Antipyrine